Pfizer’s Letter to the Duchenne Community We are pleased to share the good news that several regulatory authorities have approved the re-start of our Phase 3 ambulatory trial (CIFFREO) for […]
Today, Solid Biosciences announced a change to its corporate strategy to better align resources with goals to bring SGT-001 and SGT-003 to patients. Key Takeaways: Enrollment in IGNITE DMD, its […]
Registration Now Open for Three-Day National Conference in Orlando, Welcoming Attendees From Across the Globe Newport Beach, Calif. (March 25, 2022) – CureDuchenne, a leading global nonprofit focused on finding […]
The Event Brought the Austin Community Together for a Night of Fun with a Purpose Featuring Gourmet Food, Cocktails, Casino Games and More NEWPORT BEACH, Calif., April 6, 2022 – […]
How You Can Help Researchers Find Treatments UPDATE: This event has been postponed due to a last-minute issue and will need to be rescheduled. Don’t miss this informative webinar on […]
It is well understood that resting Ankle Foot Orthoses are recommended as standard of care for those with Duchenne muscular dystrophy. In many cases, that is the only lower extremity […]
National Center of Neurology and Psychiatry and Nippon Shinyaku announce positive results for a Phase I/II study evaluating the efficacy and safety of their exon 44 skipping drug (NS-089/NCNP-02) Results […]
In December 2020, CureDuchenne Ventures announced funding support for PepGen, Inc. to advance their Duchenne exon-skipping program to the clinic for trial. PepGen’s EDO cell-penetrating peptide platform is designed to improve the delivery of […]
Solid Biosciences issued a press release providing new, positive 2-year data from their IGNITE DMD clinical study in advance of the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. […]
